Connect with us

Policy

Psychedelics milestone for Europe: MEP Action Group launches

Published

on

European psychedelic initiative aims to impact education regulation

In a groundbreaking milestone for psychedelics in Europe, a cross-party MEP Action Group for the Medical Use of Psychedelics was launched at an expert roundtable on 24 May.

The group’s launch results from two years of advocating from campaign groups such as Psychedelic Access and Research European Alliance (PAREA) and Psychedelics EUROPE.

Its key focus is to accelerate the preparation of the regulatory landscape for psychedelic medicines in the EU Single Market. 

Further areas of focus will include:

  • Raising awareness of best practices.
  • Promoting discussions around cost-effectiveness.
  • Advocating for a harmonised EU policy and regulatory framework.
  • Fostering drug policies based on scientific evidence and human rights, to remove barriers to scientific research and access.
  • Providing input on key European legislative dossiers such as the EU’s Comprehensive Approach To Mental Health.
See also  Netherlands establishes Commission to investigate medical use of MDMA

Currently, the Co-Chairs of the group include: Alex Agius Saliba, Malta, S&D; Frédérique Ries, Belgium, Renew; Mikuláš Peksa, Czechia, Greens-EFA; Sara Cerdas, Portugal, S&D.

Members so far include: Alviina Alametsä, Finland, Greens-EFA; Jarosław Duda, Poland, EPP; and, Robert Biedroń, Poland, S&D.

Speaking at the round table, MEP Alex Agius Saliba, Malta, S&D, stated: “Traditional treatments, while invaluable, do not provide adequate solutions for everyone. It is for these individuals that we gather here today to introduce a new era of mental health treatment. […]

“We aim to guide the policy discourse on this vital topic, advocating for the safe, ethical and regulated use of these promising treatments.” 

Tadeusz Hawrot, Founder and Executive Director of PAREA, described the development as a “pivotal moment in European mental health policy” highlighting that three EU institutions are moving full steam ahead “to give long-overdue priority to improving mental health care of EU citizens.” 

Hawrot told Psychedelic Health: “The European Commission is about to unveil its mental health strategy, the European Parliament has begun working on its own mental health report, and the Council of the EU is committed to continually prioritizing mental health via EU presidencies.

“This week, the European psychedelic medicines community is adding to this momentum. Marking the European Mental Health Week, the MEP Action Group for the Medical Use of Psychedelics has been launched. 

“This marks a significant step forward in Europe’s recognition and harnessing of the potential of psychedelic therapies for brain health conditions.

“The Group currently comprises 10 MEPs from Belgium, the Czech Republic, Finland, Malta, Luxembourg, Poland, and Portugal.”

He concluded that the next steps for the group include further growing its membership, providing input to relevant EU initiatives such as the mental health strategy and pharmaceutical revisions and organizing a public policy meeting in the Parliament in the fourth quarter of this year.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Policy

Now is the time for psychedelic access, says campaigner

Published

on

Now is the time for psychedelic access, says campaigner

Activists in Oakland recently filed a ballot put forward by Dave Hodges seeking to legalise safe and legal access to psychedelics for therapeutic uses. 

In the face of critics, Hodges has said now is the time for safe access to psychedelics.

The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.

If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.

Hodges has said: “Now is the time for safe, controlled medical access for patients in need. The way to solve the problem is not by continuing to ignore it.” 

Hodges’ solution is to create a structure for use that includes proper dosages and access to experts who can help users benefit from appropriate treatment.

The updated initiative language emphasises safety, and gives doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of conditions.

Research by the University of Michigan and Columbia University shows non-LSD hallucinogenic use on the rise and Hodges has stated that increase means that the initiative providing guidelines for use is needed more than ever. 

Hodges said he hopes Californians will read the initiative, share their thoughts about it over the holiday week and offer feedback via the initiative website, PW4CA.com, by 27 November, 2023, the deadline for modifications.

“Now is the time to provide medical and therapeutic access to psychedelics,” Hodges said. “The way to do this is through the initiative.”

Continue Reading

Policy

Transform Drugs releases groundbreaking book: How to regulate psychedelics

Published

on

Transform Drugs releases book: How to regulate psychedelics

UK charity Transform Drug Policy Foundation has published a new book ‘How to Regulate Psychedelics: A Practical Guide’ that sets out how psychedelics can be legalised and regulated for non-medical adult use.

While an increasing amount of research is pointing to the potentially beneficial effects of psychedelic treatment on mental health conditions, many people across the globe are using psychedelics outside of the clinical setting.

The book includes a set of proposals for post-prohibition policies, covering psychedelics including psilocybin, LSD, DMT and Mescaline. 

Previously, Transform’s guides on regulating stimulants and cannabis have been used to advise governments around the world on drug policy. This book seeks to inform the debates on psychedelic drug reforms taking place across the world.

Co-author and Public Affairs and Policy Manager at Transform Drug Policy Foundation, Ester Kincová, stated: “Despite psychedelic drugs being illegal, their non-medical use within society has been steadily increasing. 

“Punitive enforcement has not decreased use or eliminated supply, but it has made use more unsafe. 

“Legalising and regulating psychedelics is a pragmatic move to reduce harm. This is no longer a theoretical debate, states in the US are already recognising the need and  making moves to regulate for non-medical adult use.”

Scientific Chair of Drug Science, Professor David Nutt, added: “Once again Transform have come up with a well thought out and practical plan for the regulation of another group of currently illegal drugs – in this case psychedelics. 

“Their ideas would be both easy to implement and to engage with and will, if adopted, radically enhance the safe use of these remarkable agents.”

Proposals for regulation

The book includes a four-tiered regulation model “that attempts to manage the variety of psychedelic preparations and the different ways in which they are used”.

These include:

  • Private use, home cultivation, foraging and not-for-profit sharing.
  • Membership-based non-for-profit associations for plant-based products.
  • Licensed production and retail adaptable to different products and environments
  • Regulated commercial guided or supervised use

Additionally, a decriminalisation model is proposed which suggests that possession for personal use should no longer be an offence of any kind or be subject to any sanctions; Drugs for personal use should not be confiscated; cultivation of small amounts of plant-based drugs for personal use should be decriminalised, among other suggestions.

The book also includes topics such as embedding social justice, equity and human rights into policy design, how to think about psychedelics regulation, why regulate psychedelics and why now, and psychedelics and the UN drug treaties.

To read the book, please visit transformdrugs.org/.

Continue Reading

Policy

Oakland ballot seeks to legalise medical psychedelics

Published

on

Oakland ballot seeks to legalise medical psychedelics

Activists in Oakland have filed a ballot that seeks to legalise safe and legal access to psychedelics for therapeutic uses. 

The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.

If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.

See also  Australia reschedules psilocybin and MDMA

Additionally, it would create a statewide framework for regulating the possession, use, cultivation and production of substances for medical and therapeutic use.

The initiative has been introduced by proponent and founder of the Oakland-based Church of Ambrosia, Dave Hodges, to the California Attorney General’s office for the 2024 ballot, and will need 546,651 valid signatures to qualify.

See also  CDPRG discusses the UK's Reschedule Psilocybin campaign

The filing follows California Governor Gavin Newsom’s recent veto of Senate Bill 58, the bill that sought to decriminalise the use of certain psychedelic drugs. 

Hodges emphasised that SB58 would have been a step forward, but that it had major flaws concerning its lack of provisions to ensure access, public safety and quality control. That veto, Hodges said, compelled him to move quickly on the initiative filing.

When the California Attorney General certifies the initiative for circulation, backers will have about four and a half months to gather the required signatures for ballot placement. 

Signature collecting will begin in early December.

Continue Reading

Trending